Loading
An East German chemotherapy rediscovered in the 2000s that became the backbone partner for rituximab in follicular, mantle cell and Waldenström lymphomas.
Approved 2008 for CLL and rituximab-refractory indolent NHL. StiL and BRIGHT trials showed bendamustine-rituximab at least as effective as R-CHOP with less alopecia and neuropathy, making BR the most common first-line indolent lymphoma regimen. Prolonged lymphopenia and infections (PJP, CMV) are the main concerns; combined with obinutuzumab (GALLIUM) or acalabrutinib (ECHO).
Bifunctional alkylator causing DNA cross-links with a benzimidazole ring conferring purine-analogue-like properties; less cross-resistance with other alkylators.
1.Bendamustine slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Bendeka and Belrapzo are branded; generic bendamustine is available.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens. Plans may prefer a specific bendamustine product.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE TA216 · SMC advice: bendamustine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2008 | CLL; indolent B-cell NHL progressed within 6 months of rituximab |
| EU | 2010 | CLL, indolent NHL, multiple myeloma (national approvals) |
Read for the class this product belongs to (other alkylating drugs) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A second randomised confirmation that adding a Bruton tyrosine kinase inhibitor to first-line bendamustine-rituximab delays progression in older patients with mantle cell lymphoma, with a toxicity profile that did not improve as much as the drug's selectivity promised.
The authors' conclusion is that ibrutinib-rituximab should be considered a new standard-of-care option for first-line treatment of older patients with mantle-cell lymphoma. The subgroup split means it is clearly better than R-CHOP and roughly equivalent to bendamustine-rituximab.
Twenty-eight extra months of progression-free survival, with no survival gain and a high rate of severe adverse events in both arms. It set up the two trials that followed: ECHO, which substituted a more selective inhibitor, and ENRICH, which removed the chemotherapy.
MURANO made fixed-duration venetoclax the standard for relapsed CLL and showed that stopping therapy after a deep response is safe for most patients. It also established MRD at end of treatment as a practical guide to who is likely to stay in remission. Retreatment with venetoclax at relapse appears feasible.
One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Query for this drug: (TITLE:"Bendamustine" OR ABSTRACT:"Bendamustine" OR TITLE:"Treanda" OR ABSTRACT:"Treanda" OR TITLE:"Bendeka" OR ABSTRACT:"Bendeka" OR TITLE:"Belrapzo" OR ABSTRACT:"Belrapzo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bendamustine, not a curated reading list.
Shares A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors, Chronic lymphocytic leukaemia, first treatment, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma and the tag generic.
Shares Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT), DALY II USA/ MB-CART2019.1 for DLBCL, A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008), Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination and the tag generic.
Shares Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia, Cytotoxic chemotherapy and the tag generic.
Shares The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Relapsed and refractory classical Hodgkin lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Mantle cell lymphoma and the tag generic.
Shares Relapsed and refractory classical Hodgkin lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Diffuse large B-cell lymphoma, Cytotoxic chemotherapy and the tag generic.
Shares Infection prophylaxis in lymphoma: PJP, herpes, fungal risk and vaccination, Waldenström macroglobulinaemia, Cytotoxic chemotherapy and the tag generic.
Shares Relapsed and refractory classical Hodgkin lymphoma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Diffuse large B-cell lymphoma, Cytotoxic chemotherapy and the tag generic.
Shares Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest, Cytotoxic chemotherapy and the tag generic.